| abstract |
The present invention provides compounds useful for treating histamine H3 receptor-related pathologies. A crystal form of 4-{(1S, 2S) -2-[(4-cyclobutylpiperazin-1-yl) carbonyl] -cyclopropyl} -benzamide represented by the following formula (I) and A pharmaceutical formulation comprising the compound. [Effects] Use of the active compound is schizophrenia, narcolepsy, daytime hypersomnia, obesity, attention deficit hyperactivity disorder, pain, neuropathic pain, Alzheimer's disease, cognitive deficits, schizophrenia related disorders It is effective in the treatment of [Selection] Figure 1 |